Key result
Long-term enalapril treatment in hypertensive patients with LV hypertrophy reduced LV mass index by 39% and decreased QT dispersion from 61 to 37 ms.
Why the study?
Does enalapril improve QT dispersion and reduce LV mass in patients with systemic hypertension and LV hypertrophy?
Cohort (n=24)
Does enalapril improve QT dispersion and reduce LV mass in patients with systemic hypertension and LV hypertrophy?
Long-term enalapril treatment induces regression of LV mass and improvement in QT dispersion that persist even during short-term treatment suspension and blood pressure rebound.
Answers are grounded in this paper and cite their sources.
Enalapril was associated with LV mass regression and QT dispersion reduction in hypertensive LVH; hypothesis-generating for outcome trials.
BACKGROUND: We report the reduction of QT and QTc dispersion in patients treated for 7 years with enalapril for systemic hypertension with left ventricular (LV) hypertrophy. We assess the correlation between QT dispersion and LV mass during this period and at the end of an 8-week period of suspension of enalapril treatment after 5 years. METHODS: Twenty-four previously untreated patients with this condition took enalapril (20 mg twice daily) for 7 years, except during an 8-week period following 5-year follow-up. Cardiovascular parameters were determined by two-dimensional guided M-mode echocardiography, and QT interval was measured, in a pretreatment placebo phase, 8 weeks and 1, 3, 5, and 7 years after the start of the therapy, at the end of the 8-week suspension effected after 5 years, and 8 weeks after the end of the suspension. RESULTS: Therapy rapidly reduced blood pressure (BP) from 156/105 mmHg to normal values: 134/84 mmHg after 8 weeks' treatment, 130-84 mmHg at 7-year follow-up (P < 0.001 with respect to the placebo phase). LV mass index decreased progressively until at 5-year follow-up the reduction had reached 39% (P < 0.001), after which neither LV mass nor any other structural parameter underwent any further significant change. During this time, QT dispersion (DeltaQT) and the dispersion of "corrected" QT (DeltaQTc) decreased significantly: DeltaQT (from 61 +/- 21 to 37 +/- 13 ms) and DeltaQTc (from 67 +/- 27 to 41 +/- 16 ms). After suspension of treatment for 8 weeks following 5-year follow-up, DeltaQT was 40 +/- 14 ms and DeltaQTc was 44 +/- 17 ms; there were no significant changes either in DeltaQT and DeltaQTc or LV hypertrophy although BP had returned to pretreatment values (BP: 150 +/- 16; 101 +/- 10 mmHg). CONCLUSIONS: Long-term enalapril treatment of hypertensive patients with LV hypertrophy induces marked regression of LV mass and improvement of QT dispersion. These improvements occur on a longer timescale than improvement in BP, and are not affected by transient changes in BP values.
No takes yet. Share an insight, caveat, or question.
Seara et al. (2003) conducted a cohort in Systemic hypertension with left ventricular hypertrophy (n=24). Enalapril vs. Pretreatment placebo phase was evaluated on Blood pressure, LV mass index, and QT dispersion (p=<0.001). Long-term enalapril treatment in hypertensive patients with LV hypertrophy reduced LV mass index by 39% and decreased QT dispersion from 61 to 37 ms.
Synapse has enriched 10 related papers. Consider them for comparative context: